Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism ITGB6 inhibitors(integrin subunit beta 6 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | United States | 28 Apr 2025 | |
Pancreatic Cancer | Preclinical | United States | 28 Apr 2025 | |
Squamous Cell Carcinoma of Head and Neck | Preclinical | United States | 28 Apr 2025 | |
Transitional Cell Carcinoma | Preclinical | United States | 28 Apr 2025 |